Last edition
News about "pacibekitug"
Novartis to Acquire Tourmaline Bio for USD 48 per share
Novartis to acquire Tourmaline Bio in a USD 1.4 billion deal, gaining rights to pacibekitug—an anti-IL-6 antibody with potential in cardiovascular disease; transaction expected to close in Q4 2025.
Pacibekitug | 09/09/2025 | By Dineshwori | 162
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members